- This topic has 101 replies, 17 voices, and was last updated 2 years, 10 months ago by .
-
Posts
-
maybe it would also help if more people will take steps not to get it and not to give it to others
From JAMA:
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities (The I-TECH Study)
Key Points
Question
Does adding ivermectin, an inexpensive and widely available antiparasitic drug, to the standard of care reduce the risk of severe disease in patients with COVID-19 and comorbidities?
Findings
In this open-label randomized clinical trial of high-risk patients with COVID-19 in Malaysia, a 5-day course of oral ivermectin administered during the first week of illness did not reduce the risk of developing severe disease compared with standard of care alone.
Meaning
The study findings do not support the use of ivermectin for patients with COVID-19.
- You must be logged in to reply to this topic.